AngioDynamics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James C. Clemmer
- Full Time Employees
- 632
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 14 Plaza Drive Latham NY United States of America 12110
- IPO Date
- Jun 1, 2004
- CIK
- 0001275187
- Website
- angiodynamics.com
- Similar Companies
- Business
- AngioDynamics, Inc. designs, manufactures, and markets innovative medical devices for minimally invasive, image-guided treatments of peripheral vascular disease, oncology, and cardiovascular conditions; its core products span oncology offerings including the NanoKnife System for precise tumor ablation, Habib 4X Bipolar Resection Device, and IsoLoc Endorectal Balloon; venous therapies such as VenaCure EVLT 1470 Pro Laser System and procedure packs; vascular interventions featuring the Auryon Atherectomy System, AngioVac and AlphaVac mechanical thrombectomy systems, and ports; and diagnostic tools like the Model 1500X RF Generator and Alatus balloon. The company, founded in 1988 and headquartered in Latham, New York, operates globally with facilities in the United States, Europe, and Australasia, serving interventional radiologists, nephrologists, surgeons, and healthcare providers treating critical limb ischemia, pulmonary embolism, and cancer patients. In fiscal 2026 first quarter, AngioDynamics reported strong growth including 20.1% increase in Auryon sales to $16.5 million, 41.2% rise in mechanical thrombectomy sales to $11.3 million driven by AngioVac and AlphaVac, and 26.7% growth in NanoKnife sales to $6.4 million; it enrolled the first patient in the AMBITION BTK trial for Auryon in below-the-knee lesions and the RECOVER-AV trial for AlphaVac in intermediate-risk pulmonary embolism across Europe, Canada, and Hong Kong.
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript
AngioDynamics Q4 Earnings Call Highlights
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference